325 related articles for article (PubMed ID: 16842444)
1. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
Hung CH; Lee CM; Lu SN; Wang JH; Hu TH; Tung HD; Chen CH; Chen WJ; Changchien CS
J Viral Hepat; 2006 Jun; 13(6):409-14. PubMed ID: 16842444
[TBL] [Abstract][Full Text] [Related]
2. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
Cardoso AC; Moucari R; Figueiredo-Mendes C; Ripault MP; Giuily N; Castelnau C; Boyer N; Asselah T; Martinot-Peignoux M; Maylin S; Carvalho-Filho RJ; Valla D; Bedossa P; Marcellin P
J Hepatol; 2010 May; 52(5):652-7. PubMed ID: 20346533
[TBL] [Abstract][Full Text] [Related]
3. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
4. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
5. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
Moon C; Jung KS; Kim DY; Baatarkhuu O; Park JY; Kim BK; Kim SU; Ahn SH; Han KH
Dig Dis Sci; 2015 Feb; 60(2):573-81. PubMed ID: 25236421
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
Harada N; Hiramatsu N; Oze T; Morishita N; Yamada R; Hikita H; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
J Viral Hepat; 2014 May; 21(5):357-65. PubMed ID: 24716638
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.
Fernández-Rodríguez CM; Alonso S; Martinez SM; Forns X; Sanchez-Tapias JM; Rincón D; Rodriguez-Caravaca G; Bárcena R; Serra MA; Romero-Gómez M; Fernandez I; Garcia-Samaniego J; Fuente J; Solá R; Moreno-Otero R; Planas R;
Am J Gastroenterol; 2010 Oct; 105(10):2164-72; quiz 2173. PubMed ID: 20700116
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.
Floreani A; Baldo V; Rizzotto ER; Carderi I; Baldovin T; Minola E
J Clin Gastroenterol; 2008 Jul; 42(6):734-7. PubMed ID: 18285717
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.
Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Maruyama T; Tanabe Y; Satoh T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
J Hepatol; 2013 Mar; 58(3):495-501. PubMed ID: 23099187
[TBL] [Abstract][Full Text] [Related]
10. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
[TBL] [Abstract][Full Text] [Related]
11. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.
Ishikawa T; Higuchi K; Kubota T; Seki K; Honma T; Yoshida T; Kamimura T
Hepatogastroenterology; 2012; 59(114):529-32. PubMed ID: 22024226
[TBL] [Abstract][Full Text] [Related]
12. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
[TBL] [Abstract][Full Text] [Related]
13. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
14. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
Huang CF; Yeh ML; Tsai PC; Hsieh MH; Yang HL; Hsieh MY; Yang JF; Lin ZY; Chen SC; Wang LY; Dai CY; Huang JF; Chuang WL; Yu ML
J Hepatol; 2014 Jul; 61(1):67-74. PubMed ID: 24613362
[TBL] [Abstract][Full Text] [Related]
15. Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.
Honda T; Ishigami M; Masuda H; Ishizu Y; Kuzuya T; Hayashi K; Itoh A; Hirooka Y; Nakano I; Ishikawa T; Urano F; Yoshioka K; Toyoda H; Kumada T; Katano Y; Goto H
J Gastroenterol Hepatol; 2015 Feb; 30(2):321-8. PubMed ID: 25091027
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Intervirology; 2013; 56(1):37-45. PubMed ID: 23037768
[TBL] [Abstract][Full Text] [Related]
19. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
20. [Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection].
Ji F; Dang S; Cai Z; Xue H; Huang N; Liu L; Zhang S; Guo Y; Jia X; Wang Y; Li Z; Deng H
Zhonghua Gan Zang Bing Za Zhi; 2015 Sep; 23(9):647-52. PubMed ID: 26524356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]